Genequantum Healthcare Co. Ltd. will work with Aimed Bio Inc. to co-develop an antibody-drug conjugate (ADC) to treat brain and other cancers, working toward an IND filing in 2023. Aimed Bio will focus on antibody development, while Genequantum will work on linker-payload development. “Since we have a plan to market and sell the product globally, we will conduct a phase I clinical trial in the U.S., Australia, South Korea, and China as a priority,” Do-Hyun Nam, founder, chairman, and chief technology officer of Aimed, told BioWorld.

Biontech SE and Medigene AG have signed a three-year research collaboration to develop T-cell receptor (TCR) based immunotherapies against cancer. Medigene will receive €26 million ($29.5 million) up front and could receive hundreds of millions of euros per drug in milestone payments from the deal, which will also covers research funding for the period of the collaboration.